

SciFluor Patent Release

Final Version

December 12, 2027

1. Introduction

This Patent Release is made effective as of December 12, 2027 by SciFluor Life Sciences, Inc., a Delaware corporation with its principal place of business at Cambridge, Massachusetts.

The purpose of this Release is to formally disclose and clarify the terms and scope of the Company's patent portfolio covering novel fluorinated compounds and related therapeutic inventions developed by SciFluor, including but not limited to compositions, methods of synthesis, and pharmaceutical applications.

2. Background

SciFluor Life Sciences is a clinical-stage biopharmaceutical company dedicated to discovering and developing differentiated, best-in-class therapeutics leveraging proprietary fluorine chemistry. The Company's innovative portfolio addresses diseases across retinal disorders, central nervous system (CNS) disorders, inflammatory diseases, and other indications.

SciFluor's patent portfolio comprises granted and pending patent applications in multiple jurisdictions, protecting core technologies including but not limited to:

- Novel fluorinated small molecules with enhanced pharmacological profiles;
- Methods of synthesizing and manufacturing fluorinated compounds;
- Specific therapeutic applications of fluorinated compounds in neurological, ophthalmic, and inflammatory diseases.

3. Patent Portfolio Overview

As of the Effective Date, SciFluor's patent portfolio includes the following key patents and patent applications:

| Patent Number / Application Number | Title / Subject Matter | Jurisdiction | Status | Expiry Date |
|---------------------------------------|--|-------------------|---------|----------------|
| US 11,234,567 B2 | Fluorinated Compounds for CNS Disorders | United States | Granted | l 2042 |
| EP 3,456,789 A1 | Methods of Synthesizing Fluorinated Therapeutics | European Union | Pending | g TBD |
| JP 2027-123456 | Novel Fluorinated Molecules for Retinal Disease Treatment | Japan | Granted | l 2043 |
| CN 10987654 A | Pharmaceutical Compositions Containing Fluorinated Active Agents | China | Pending | ; TBD |

4. Scope of Patent Rights

SciFluor asserts exclusive rights within its patent portfolio including but not limited to:

- The manufacture, use, sale, offer for sale, import, and export of patented fluorinated compounds;
- The use of proprietary synthetic methods and processes covered by patent claims;
- The development and commercialization of pharmaceutical compositions comprising patented fluorinated molecules.

5. Licensing and Collaboration

SciFluor is open to discussions regarding licensing opportunities and collaborative partnerships to maximize the therapeutic and commercial potential of its fluorine chemistry innovations. Interested parties are invited to contact the Company's Business Contact Us